Assessment of early response to tyrosine kinase inhibitor (erlotinib) in stage IIIB/IV NSCLC by PET/CT

被引：0
|
作者：
Benz, Matthias [1 ]
Walter, Franziska [2 ]
Garon, Edward [3 ]
Phelps, Michael [2 ]
Czernin, Johannes [2 ]
Allen-Auerbach, Martin [1 ]
机构：
[1] Univ Freiburg, Nucl Med, Freiburg, Germany
[2] Univ Calif Los Angeles, Mol & Med Pharmacol, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Med, Los Angeles, CA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2011年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
426
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib
    John F. Deeken
    Jan H. Beumer
    Nicole M. Anders
    Teresia Wanjiku
    Milan Rusnak
    Michelle A. Rudek
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 813 - 819
  • [22] Early results of a phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy (CT-RT) for stage IIIA/IIIB NSCLC
    Rengan, Ramesh
    Mick, Rosemarie
    Lin, Lilie L.
    Maity, Amit
    Gupta, Anjali K.
    Evans, Tracey L.
    Stevenson, James
    Langer, Corey J.
    Kucharczuk, John
    Friedberg, Joseph
    Prendergast, Susan
    Driesbaugh, Jason
    Hahn, Stephen M.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S519 - S519
  • [23] Dynamic FDG PET-CT in stage IV melanoma: early therapy response evaluation to ipilimumab
    Sachpekidis, C.
    Dimitrakopoulou-Strauss, A.
    Strauss, L. G.
    Schulz, C.
    Hassel, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S482 - S483
  • [24] Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
    Malet, Julie
    Ancel, Julien
    Moubtakir, Abdenasser
    Papathanassiou, Dimitri
    Deslee, Gaetan
    Dewolf, Maxime
    LIFE-BASEL, 2023, 13 (04):
  • [25] A gene expression profile indicative of early stage HER2 tyrosine kinase inhibitor response.
    O'Neill, Fiona
    Madden, Stephen F.
    Clynes, Martin
    Doolan, Padraig
    Crown, John
    Aherne, Sinead
    O'Connor, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Methods for Evaluating Early Response to Erlotinib Treatment Using FDG-PET/CT
    Fledelius, Joan
    Larsen, Anne W.
    Khalil, Azza Ahmed
    Frokiaer, Jorgen
    Meldsaard, Peter
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S589 - S589
  • [27] A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
    John P. Crandall
    Abdel K. Tahari
    Rosalyn A. Juergens
    Julie R. Brahmer
    Charles M. Rudin
    Giuseppe Esposito
    Deepa S. Subramaniam
    Michael V. Knopp
    Nathan C. Hall
    Prateek Gajwani
    Jeffrey P. Leal
    Martin A. Lodge
    Joo H. O.
    Edward W. Gabrielson
    Lalitha K. Shankar
    Richard L. Wahl
    EJNMMI Research, 7
  • [28] 18FDG PET/CT in the early assessment of NSCLC response to immunotherapy: results from a prospective study
    Humbert, O.
    Cadour, N.
    Paquet, M.
    Chardin, D.
    Otto, J.
    Darcourt, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S154 - S155
  • [29] PET-CT for visualizing the pathophysiology of COPD in patients with early-stage NSCLC
    Kobayashi, Haruki
    Naito, Tateaki
    THORACIC CANCER, 2024, 15 (34) : 2456 - 2457
  • [30] Application of kinase activity profiles to predict response to erlotinib in a neoadjuvant setting in early stage non-small call lung cancer (NSCLC)
    Hilhorst, R.
    Schaake, E.
    van Pel, R.
    Nederlof, P.
    Houkes, L.
    de Wijn, R.
    Ruijtenbeek, R.
    van den Heuvel, M.
    Baas, P.
    Klomp, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345